MEDICAL DEVICES

Nov 12, 2026

Tandem Diabetes Care has recalled 80,938 Mobi insulin pumps due to false occlusion alarms that stop insulin delivery, a Class I recall by the FDA. The company has reported 230 adverse events requiring medical intervention or hospitalization, though no deaths. The issue stems from increased friction in the pump's drive module, which can falsely detect a blocked line, leading to high blood glucose if not addressed.

Nov 11, 2026

Rockville-based MaxCyte, Inc. is set to acquire Florida's Akron BioProducts LLC for approximately $151.8 million, a move expected to nearly double MaxCyte's revenue and expand its role in the cell therapy industry. The acquisition will enhance MaxCyte's presence across cell therapy manufacturing stages, increase recurring revenue, and accelerate its path to profitability. The deal involves $105 million in cash, 20.6 million shares of common stock, and $20 million in deferred payments, supported by a new credit facility of up to $75 million.

Nov 11, 2026

Align Technology has appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors, replacing the retiring Andrea Saia. Blackford brings extensive experience in global healthcare, medical technology, and digital innovation from his roles at iRhythm Technologies, Dexcom, NuVasive Inc., and Zimmer Holdings. Align Technology credits Saia for her significant contributions to the company's growth and strategic oversight during her 13-year tenure.

Nov 11, 2026

Jonathan Rose highlights three healthcare stocks—Prothena Corporation (PRTA), Rapport Therapeutics, Inc. (RAPP), and Azenta, Inc. (AZTA)—that have caught his attention due to insider purchases or corporate buybacks. While these actions signal confidence, Rose emphasizes that they are merely starting points for research, not immediate buy recommendations, and stresses the importance of further investigation into financial strength and catalysts. He details why each stock is on his watchlist, noting their balance sheets, upcoming clinical data, and growth outlooks, while also cautioning about the inherent risks in the biotechnology sector and market conditions.

Nov 11, 2026

SANUWAVE Health reported a 24% revenue decline in Q3 2026 to $8.6 million, primarily due to a 73% drop in UltraMist system sales, although applicator revenue grew 2%. The company was significantly impacted by CMS's proposed rule affecting reimbursement rates for skin substitutes and a proposed reduction in the 97610 code reimbursement. Despite these challenges, SANUWAVE is pivoting its sales strategy towards hospitals, targeting Hospital-Acquired Pressure Injuries (HAPI) and sees potential opportunities in restructuring the 97610 code for better alignment with complex wound care.

Nov 11, 2026

Guardant Health has expanded its Guardant360 Liquid blood test with five new epigenomic applications designed to improve breast and lung cancer treatment selection. These additions use the company's InfinityAI platform to combine genomic and epigenomic signals, aiming to inform therapy choices when conventional mutation markers are insufficient. The company reported $231.3 million in third-quarter revenue, with oncology test volume up 58 percent year-over-year.

Nov 11, 2026

Stereotaxis reported a 20% year-over-year revenue increase to $8.9 million for Q3 2026, driven by new system installations and increased catheter sales. The company is undergoing two major transformations: shifting to easily installed systems like Genesis X and developing disposable interventional catheters for recurring revenue. Despite supply constraints for Magic catheters, Stereotaxis is pursuing alternative options and secured a convertible note financing of up to $24 million to support operations until anticipated profitability within the next year.

Nov 11, 2026

Neuronetics Inc. (Nasdaq: STIM) granted 123,300 restricted stock units to 14 non-executive employees on November 4, 2026, as an incentive for recruitment and retention. These equity awards, approved under Nasdaq Listing Rule 5635(c)(4), will mostly vest in three equal annual installments, beginning on the first anniversary of the grant date. The awards aim to link employee compensation to continued service and support the Malvern-based mental health technology company's personnel strategy.

Nov 11, 2026

Abbott's UltiSynq defibrillation lead has received simultaneous market approvals in the US and Europe, offering a new option for patients needing both conduction system pacing and defibrillation protection. The approvals were supported by the ASCEND CSP trial, which demonstrated a 97.5% major complication-free rate and high implantation success for the device, designed to treat irregular heart rhythms by directly targeting the heart's natural electrical pathways. This product expands Abbott’s cardiac rhythm management portfolio, providing a solution for patients indicated for implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) therapy.

Nov 11, 2026

Enovis Corporation Director Sharon L. Wienbar recently acquired 1,831 shares of the company's common stock through two open-market transactions on November 6 and November 9, 2026. These purchases increased her direct ownership to 43,777 shares. The transactions, reported via a Form 4 to the SEC on November 10, 2026, were executed at prices of $27.55 and $26.98 per share, respectively.

Nov 11, 2026

Neuronetics Inc. (Nasdaq: STIM) achieved operating profitability in Q3 2026, driven by a 20.1% increase in revenue from its Greenbrook psychiatric clinics. This led to a narrowed net loss, improved gross margins, and reduced operating expenses, prompting an optimistic revision of its full-year financial forecasts. The company is also pursuing FDA clearance for an accelerated TMS treatment protocol and integrating its NeuroStar technology with Wave Neuroscience for PTSD treatment.

Nov 10, 2026

Freenome (NASDAQ: FRNM) held its first earnings call as a public company, reporting a total revenue of $183.5 million for Q3 2026, primarily due to FDA approval and commercial launch of Simple Screen CRC. The company raised $310 million through its NASDAQ IPO and is focused on expanding its AI-enabled cancer screening platform and product pipeline, including new lung cancer tests and strategic partnerships with Abbott and Roche. Freenome anticipates future growth through continued innovation in test development, aiming for additional single and multi-cancer tests, while also working to broaden reimbursement coverage.

Nov 10, 2026

Stephens Investment Management Group LLC has significantly increased its stake in AXOGEN (AXGN) by adding 871,949 shares to its portfolio, as per a recent SEC 13F filing for the Q3 2026 reporting period. This move comes amidst varied institutional investor activity, with 139 firms adding shares and 106 decreasing positions, while AXOGEN insiders have exclusively sold shares in the past six months.

Nov 10, 2026

TELA Bio reported Q3 2026 revenue of $19 million, an 8% year-over-year decrease, despite sequential growth in U.S. hernia revenue and 18% growth in European revenue. The company implemented a $17 million cost reduction plan, improved its adjusted EBITDA loss by 55% sequentially, and regained Nasdaq compliance. Strategic shifts include a focus on high-ASP procedures, strengthened clinical validation with new publications, and FDA clearance for the Liora Monofilament Scaffold, aiming for a return to double-digit growth.

Nov 10, 2026

Electromed reported strong first-quarter fiscal 2027 results, with revenue growing 10.6% to $18.7 million and operating income increasing 30.7%. Home care revenue, their primary growth driver, rose 17.6% due to increased sales reps and productivity, while other channels saw declines. The company emphasized strategic initiatives like expanding patient access, enhancing commercial reach, and converting bronchiectasis awareness into SmartVest prescriptions, and announced CEO Jim Cunniff's retirement in April 2027.

Nov 10, 2026

LENSAR Inc. reported its Q3 2026 earnings, showcasing a 17% year-over-year surge in recurring revenue to $12.6 million, now comprising 89% of total revenue. Despite a 1% decline in total revenue to $14.1 million due to lower capital system sales, the company achieved a positive Adjusted EBITDA of $1.7 million and improved gross margins to 58%. LENSAR's CEO, Nicholas Curtis, addressed challenges in system sales, particularly outside the U.S., while outlining future plans for automation, robotic docking, and new corneal procedures.

Nov 10, 2026

908 Devices Inc. reported strong Q3 2026 results with $19 million in revenue, a 35% year-over-year increase, driven by FTIR product strength and NIRLab integration. The company shipped a record 300+ devices, expanding its installed base to approximately 4,400, and raised its full-year 2026 revenue guidance to $68.5 million to $70 million. Management highlighted progress in scaling proven platforms, extending leadership in aerosol detection, and strengthening recurring revenue through connected services like NIRLab, while also making strides towards reducing adjusted EBITDA losses.

Nov 10, 2026

GE HealthCare Technologies Inc. (GEHC) has enhanced its Vscan Air handheld ultrasound system with two new AI-assisted capabilities: Lung Guidance and AutoAS. These tools are designed to streamline lung ultrasound image acquisition and aid in assessing moderate-to-severe aortic stenosis at the point of care. The expansion of its cardiopulmonary AI suite aims to help clinicians make more informed decisions, especially when access to formal imaging or specialist interpretation is limited, potentially strengthening GE HealthCare's position in the point-of-care ultrasound market.

Nov 10, 2026

NovoCure's stock took a hit after the FDA issued a "not approvable" letter for its investigational device, Optune Mya, intended for lung cancer brain metastases. While the device met its primary endpoint, it fell short on key secondary endpoints, leading to the FDA's decision based on "uncertainty around the degree of clinical benefit." The company plans to evaluate the response and seek a path to approval, but analysts express skepticism about the stock as other Optune products mature and new competitors emerge.

Nov 10, 2026

AdaptHealth (AHCO) has seen recent investor attention after reporting a third-quarter goodwill impairment, raising its 2026 revenue guidance, and posting new quarterly results. The company's shares have rebounded significantly over the past 30 and 90 days despite a year-to-date decline, with investors now evaluating whether the increased revenue guidance and progress on capitated contracts outweigh concerns about the goodwill hit and ongoing losses. Simply Wall St's analysis suggests AdaptHealth is currently 11% undervalued.

Nov 10, 2026

Shares of Nano-X Imaging Ltd (NASDAQ: NNOX) are trading higher after its subsidiary, Nanox.AI, announced a commercial collaboration with Dosy Health to support the planned commercialization of its CT-based cardiac solution in Thailand. This agreement comes as Nano-X is implementing a plan to cut annualized operating expenses by 25% to 30% by the end of Q1 2027. The stock rebounded significantly from an all-time low.

Nov 10, 2026

COMMERZBANK AKTIENGESELLSCHAFT /FI has increased its stake in Abbott Laboratories (ABT) by adding 603,275 shares to its portfolio, as per a recent SEC 13F filing for the report period ending September 30, 2026. The article also details other significant institutional investor activities, insider trading, government contracts awarded to ABT, and congressional stock trading involving ABT shares. Analyst price targets for ABT are also provided, with a median target of $115.0.

Nov 10, 2026

Stryker (SYK) stock has seen a 6.9% decline over the past year, trading near a price point ($325.73) where it bounced strongly in 2024 but has since fallen 5% on subsequent returns. While Stryker's strong operating margin and organic sales growth in MedSurg and Neurotechnology offer a plausible reason for a bounce, a slowing hip and knee business and execution risk on capital equipment sales pose a significant threat, potentially pushing the stock to the next support level at $293.30. Investors should watch for fourth-quarter organic sales growth and improvements in U.S. knee and hip sales in the upcoming January 2027 earnings report.

Nov 10, 2026

Shares of Boston Scientific Corp. (BSX) rose 1.54% to $44.70 on Tuesday, outperforming the broader market which saw the S&P 500 Index (SPX) fall 0.38% and the Dow Jones Industrial Average (DJIA) fall 0.30%. This marked the second consecutive day of gains for the stock.

Nov 10, 2026

Hallador Energy (HNRG) reported a net loss of $4.5 million in Q3 2026 due to a debt extinguishment loss and increased power costs, despite a 77% sequential increase in Merom generation. The company is advancing its Turtle Creek natural gas project, targeting a final investment decision by year-end 2026 and commercial operation by H2 2028, aiming to double its value to $1.6 billion. Hallador has secured $3 billion in contracted forward sales, primarily with investment-grade utilities, and is focused on maximizing Merom's availability to capitalize on rising energy and capacity prices.

Nov 10, 2026

MaxCyte reported a 49% year-over-year increase in third-quarter 2026 revenue, reaching $10.2 million, and narrowed its net loss to $4.8 million. The company subsequently raised its full-year 2026 revenue guidance to at least $34.5 million, excluding the proposed Akron Bio acquisition. This updated forecast includes approximately $28 million in core revenue and anticipates about 15% core revenue growth in the second half of the year.

Nov 10, 2026

Hagens Berman has filed a securities class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) following disclosures of a U.S. Department of Justice Civil Investigative Demand, significant cuts to revenue guidance, and sales force disruption. Investors who suffered substantial losses between July 25, 2023, and August 6, 2026, are encouraged to contact the firm before the January 8, 2027, lead plaintiff deadline to evaluate their legal rights and recovery options. The lawsuit alleges that CVRx may have misled investors regarding its sales force and Medicare Advantage reimbursement rates.

Nov 10, 2026

Medtronic PLC (MDT) shares fell by 1.17% on Tuesday, closing at $101.59, as the broader stock market also experienced a downturn. The company's stock underperformed both the S&P 500 and the Dow Jones Industrial Average, which also saw declines. Medtronic PLC finished the trading session 4.46% below its 52-week high.

Nov 10, 2026

Brainsway (NASDAQ:BWAY) reported quarterly earnings of $0.05 per share, missing analyst estimates by $0.07, despite revenue of $18.15 million which exceeded expectations. The company saw strong year-over-year revenue growth of 34% and a 44% increase in system shipments, with its global installed base surpassing 2,000 systems. Brainsway's management anticipates full-year 2026 results at the upper end of guidance, driven by improved profitability and expanding reimbursement coverage for its Deep TMS protocols.

Nov 10, 2026

Senseonics Holdings Inc. saw its stock rise on Tuesday following better-than-expected third-quarter financial results and an increased fiscal 2026 revenue guidance. The company's implantable continuous glucose monitor, Eversense 365, drove a significant revenue beat. Raymond James also upgraded the stock, and other analysts lifted their price targets.

Nov 10, 2026

Perspective Therapeutics Inc (NYSE: CATX) reported a narrower Q3 loss of 27 cents per share compared to 35 cents a year ago, though sales significantly dropped to $20,000 from $209,000. Despite encouraging clinical findings, analysts from Piper Sandler and Wedbush lowered their price targets for the stock, which subsequently fell 2.4% to $0.84.

Nov 10, 2026

Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.

Nov 10, 2026

Ronda E Stryker, a Director at Stryker (NYSE: SYK), sold 550,000 shares of the company's stock for a total of $178.92 million on November 9. The article provides an overview of Stryker's financial performance, including revenue growth, profitability metrics, and debt management, and discusses the importance of insider transactions for investors. Stryker's shares were down by 1.86% to $319.66 following the disclosure.

Nov 10, 2026

908 Devices reported a strong Q3 2026 with revenue up 35% year-over-year to $19 million, shipping a record 300+ devices and expanding its installed base to approximately 4,400. The company raised its full-year revenue guidance to $68.5-$70 million and is making progress towards reducing its adjusted EBITDA loss. Key growth drivers for 2027 include Near Lab, the next-generation MX908, and potential AVCAD program orders.

Nov 10, 2026

LENSAR reported a 1% decrease in Q3 2026 revenue to $14.1 million, mainly due to lower system sales, but saw a 17% increase in recurring revenue to $12.6 million. Procedure volume grew 12% year-over-year, and market share expanded to 24.5%. The company emphasized its strategic focus on expanding its ALLY system installed base, increasing utilization, and advancing robotic docking capabilities slated for Q1 2027, while also securing a $10 million revolving line of credit to boost liquidity.

Nov 10, 2026

BrainsWay reported a strong Q3 2026, with revenue increasing 34% year-over-year to $18.1 million, driven by a 44% growth in Deep TMS system shipments. The company's global installed base now exceeds 2,000 systems, and its strategic initiatives include expanding clinical indications, enhancing reimbursement for SWIFT protocol and OCD treatments, and developing international markets. Management is optimistic about future growth, expecting full-year 2026 results at the upper end of guidance and continued improvements in margins and profitability through its recurring revenue model.

Nov 10, 2026

TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million, an 11% year-over-year increase, driven by TriNav adoption. The company received FDA clearance for TriNav Advance, expanding its PEDD technology. TriSalus updated its 2026 revenue guidance to $46-$48 million, reflecting slower sales team ramp-up and shifts in procedure trends, but expressed optimism for 2027 due to expected improved productivity, the TriNav Advance launch, and favorable reimbursement changes.

Nov 10, 2026

Envoy Medical Inc. (NASDAQ: COCH) has regained compliance with Nasdaq's minimum bid price requirement. This was achieved after its Class A common stock maintained a closing bid price of $1.00 or more for ten consecutive trading days, following a 1-for-10 reverse stock split that became effective on October 26, 2026. The company is now compliant with all applicable continued listing standards and will continue trading on The Nasdaq Capital Market.

Nov 10, 2026

Nuwellis, Inc. has secured exclusive U.S. distribution rights for the Zorro-Flow® pediatric urine collection system, expanding its presence in neonatal and pediatric critical care. This non-invasive solution is designed to improve urine output collection and monitoring in neonates and small children, addressing an unmet need for accurate kidney function assessment. The agreement is expected to broaden Nuwellis' relationships with pediatric care teams and strengthen its commercial footprint, with full U.S. commercialization planned for the first quarter of 2027.

Nov 10, 2026

Intelligent Bio Solutions Inc. announced record fiscal first-quarter 2027 revenue of $1.39 million, marking its sixth consecutive quarter of year-over-year growth. This was driven by a 32% year-over-year increase in higher-margin cartridge sales, which now account for 61% of total revenue, and an expanded gross profit margin of 54.5%. The company also submitted its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, moving closer to entering the U.S. drug screening market.

Nov 10, 2026

Senseonics Holdings (SENS) saw an 18% surge in premarket trading after reporting third-quarter results that exceeded expectations and raising its full-year revenue outlook. The company's revenue reached $19.6 million, a 140% increase year-over-year, and GAAP EPS also beat estimates. Senseonics highlighted growth opportunities in Eversense 365 adoption and the Beta Bionics iLet integration.

Nov 10, 2026

Co-Diagnostics (NASDAQ:CODX) led pre-market healthcare and biotech gainers on Tuesday with a 29.47% rise, despite no identified catalyst. Other significant gainers included Skye Bioscience, Inc. (NASDAQ:SKYE), Harrow, Inc. (NASDAQ:HROW) due to Q3 results, Senseonics (NASDAQ:SENS) on raised guidance, and IceCure Medical (NASDAQ:ICCM). Many of these gains in thinly traded small-cap stocks are noted to be susceptible to reversals at market open.

Nov 10, 2026

M&G PLC reduced its stake in Medtronic PLC by 4.8% during the third quarter, selling 185,546 shares and now owning 3,716,148 shares valued at $319.59 million. Other institutional investors also adjusted their positions, while Medtronic reported strong earnings, beating analyst estimates with $1.45 EPS and $9.76 billion in revenue. The company also announced a quarterly dividend of $0.72 per share.

Nov 10, 2026

Welch & Forbes LLC has acquired a significant new stake in Stryker Corporation (NYSE:SYK), purchasing 519,163 shares valued at approximately $142.97 million during the third quarter. This acquisition makes Stryker the 14th largest position in Welch & Forbes LLC's portfolio, representing about 1.7% of its total holdings. The article also details recent insider selling activity and updated analyst price targets for Stryker.

Nov 10, 2026

Alps Advisors Inc. increased its stake in Medtronic PLC by 39.8% in the third quarter, purchasing an additional 12,505 shares and bringing its total holdings to 43,963 shares valued at approximately $3.8 million. Medtronic currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $102.88, and recently reported strong quarterly earnings and a dividend of $0.72 per share. Insider selling also occurred, with CEO Geoffrey Martha and EVP Harry Kiil reducing their positions in the company.

Nov 10, 2026

LENSAR, Inc. reported its third-quarter 2026 financial results, with total revenue slightly down to $14.1 million from $14.3 million in the prior year, attributed to typical summer seasonality impacting system sales. Despite the decline in overall revenue, the company saw a 17% year-over-year increase in recurring revenue to $12.6 million and a 12% rise in procedure volume, demonstrating the growing strength of its operational foundation. LENSAR placed 10 ALLY Robotic Cataract Laser Systems, expanding its installed base to approximately 225 systems and reinforcing its focus on innovation and disciplined commercial execution for sustainable long-term growth.

Nov 10, 2026

Director William Burke of Tactile Systems Technology (NASDAQ:TCMD) sold 5,000 shares of company stock for $135,000, reducing his stake by 9.08%. The transaction was carried out under a pre-arranged Rule 10b5-1 plan. This insider sale comes as the company reported quarterly EPS above consensus but slightly missed revenue expectations, with analysts maintaining a "Moderate Buy" rating for the stock.

Nov 9, 2026

Stryker Director Ronda Stryker sold 550,000 shares of SYK stock for approximately $178.9 million, reducing her holdings by 24.43%. This insider sale follows Stryker's recent quarterly results that missed earnings and revenue expectations, although revenue still grew 7.6% year-over-year. Despite several analysts lowering their price targets or ratings, the consensus view on the stock remains a "Moderate Buy."

Nov 9, 2026

Berman Tabacco has filed a class action lawsuit against CVRx, Inc. and its officers, alleging that the medical device company made false and misleading statements about its revenue growth, sales practices, and regulatory compliance. The lawsuit claims that CVRx engaged in improper marketing, kickbacks, and provided false information to government health insurance programs, exposing the company to liability under the False Claims Act and Anti-Kickback Statute. These allegations emerged after CVRx disclosed a civil investigative demand from the U.S. Department of Justice and cut its 2026 revenue outlook, leading to a significant drop in its stock price.

Nov 9, 2026

Edwards Lifesciences VP Donald Bobo Jr. sold 48,900 shares of the company's stock for approximately $5.04 million on November 9, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction significantly reduced his holdings by 68.2%, leaving him with 22,798 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and the stock traded up 2.5% following the news.

Nov 9, 2026

Senseonics Holdings reported a record Q3 2026 revenue of $19.6 million, a 140% increase year-over-year, largely due to the success of its Eversense 365 product. The company raised its full-year revenue guidance to $68 million to $70 million, attributing the growth to expanded commercial operations, pump partnerships, and the forthcoming Freedom CGM system. Management anticipates reaching cash flow breakeven shortly after the Freedom system's planned launch in 2028, underscoring its commitment to product differentiation and market penetration.

Nov 9, 2026

RadNet reported a 22.1% increase in revenue for its third quarter of 2026, reaching $638.3 million, driven by higher advanced imaging volumes, new centers, acquisitions, and improved reimbursement. Net income declined slightly to $4.2 million, but adjusted EBITDA rose 23.8% to $105 million. The company also raised its full-year 2026 guidance for the imaging center segment.

Nov 9, 2026

This article highlights several companies whose stocks experienced significant movement this week following their latest financial reports or major announcements. Sprout Social, Redwire, Inspire Medical Systems, and Fastly all saw their stock prices fall after reporting third-quarter results that either missed analyst estimates, showed a net loss, or failed to impress. Marvell Technology's stock also declined after it announced an agreement to acquire Lumentum in an all-stock transaction.

Nov 9, 2026

UBS Group raised its price target for TransMedics Group (NASDAQ:TMDX) to $88.00 from $77.00, while maintaining a "neutral" rating. This new target implies a potential downside of 6.19% from the stock's previous close. The medical technology company recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.51 and revenue of $203.01 million, representing a 41.1% year-over-year increase.

Nov 9, 2026

Tandem Diabetes Care has appointed Jeannette Bankes as its new president and CEO, effective November 16, 2026. She will succeed John Sheridan, who is retiring at the end of 2026 after over a decade of service. Bankes brings more than 30 years of global operating experience, most recently serving as president and CEO of GE HealthCare’s Patient Care Solutions segment.

Nov 9, 2026

The FDA has declined to approve Novocure's Optune Mya device for non-small cell lung cancer that has spread to the brain, citing uncertainty around its clinical benefit. While the Phase 3 METIS trial showed the device delayed intracranial progression, it did not improve overall survival or neurocognitive outcomes. This decision is a setback for Novocure's planned early 2027 launch, though the company is evaluating feedback and intends to meet with the FDA.

Nov 9, 2026

NANO-X IMAGING LTD (NASDAQ: NNOX) announced that its Board of Directors has approved a plan to reduce costs and improve operational efficiency. This plan, which includes workforce reductions and other operational adjustments, aims for a 25%-30% reduction in annualized operating expenses by the end of Q1 2027. The company intends to focus on accelerating commercialization of Nanox.ARC and Nanox Imaging Network, strengthening commercial partnerships, improving operational efficiency, and enhancing financial flexibility.

Nov 9, 2026

Abbott Laboratories recently received FDA approval for its Amplatzer Paraclose PVL Occluder and launched its Oncodetect MRD test, diversifying its portfolio in complex heart procedures and cancer monitoring. Despite these positive developments, the stock is down 11.48% year-to-date and trades about 7% below the average analyst target. Simply Wall St's analyst consensus suggests ABT is 9% undervalued with a fair value estimate of $120.26, while its P/E ratio of 40.7x is higher than industry and peer averages, indicating a premium valuation.

Nov 9, 2026

RadNet, Inc. reported record third-quarter revenue of $683 million, a 22.1% increase year-over-year, and adjusted EBITDA of $105 million, a 23.8% increase, driven by demand in advanced imaging, new centers, and joint ventures. The company announced the acquisition of ONRAD, forming a new Radiology Professional Services segment, expected to add significant revenue and EBITDA. RadNet also raised its 2026 full-year guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow due to strong performance and digital health growth.

Nov 9, 2026

Shares of Insulet Corp. (PODD) advanced 2.25% to $149.81 on Monday, ending a two-day losing streak. Despite the rise, the stock underperformed the broader market, as the S&P 500 Index (SPX) rose 2.35% and the Dow Jones Industrial Average (DJIA) gained 2.15%.

Nov 9, 2026

Novocure Ltd. (NASDAQ: NVCR) experienced a stock decline after the FDA issued a Not Approvable Letter for its Optune Mya device, intended for brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the clinical benefit. This regulatory setback follows a previous Phase 3 TRIDENT study that failed to significantly improve overall survival in glioblastoma patients.

Nov 9, 2026

Vascular Technology Incorporated (VTI) has appointed David Pierce, a former executive vice president at Boston Scientific Corp., to its Board of Directors. Pierce brings over 30 years of experience in the medical device and healthcare technology markets, and his expertise is expected to help VTI expand and strengthen customer relationships. This appointment aims to support VTI's growth in surgical devices, particularly in endoscopic therapies.

Nov 9, 2026

Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both adjusted earnings per share and net sales. The company also announced that its shareholders have approved the merger agreement with Merck KGaA, an important step towards the completion of the $11.3 billion acquisition expected by late 2026 or early 2027. This merger aims to strengthen their global presence and service capabilities across the life sciences value chain.

Nov 9, 2026

Profound Medical Corp. announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on November 12, 2026, at 8:40 a.m. Eastern Time. Mr. Fabian, along with CEO Arun Menawat and CFO Matthew Sobczyk, will also conduct one-on-one meetings with investors. The company, a commercial-stage medical device firm, specializes in interventional MRI procedures, including its TULSA-PRO and Sonalleve platforms.

Nov 9, 2026

Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 2.3% year-over-year increase, driven by strong performance in Limb Reconstruction and Therapeutic Solutions, despite challenges in the U.S. Spine segment due to market softness and supplier delays. The company updated its full-year 2026 guidance, focusing on strategic initiatives to improve U.S. Spine execution, simplify its product portfolio, and invest in high-growth areas while navigating temporary regulatory impacts from European MDR strategy. Management remains committed to disciplined execution and long-term value creation.

Nov 9, 2026

TriSalus Life Sciences Inc (TLSI) is scheduled to release its Q3 2026 earnings on November 10, 2026, with consensus estimates predicting $14.02 million in revenue and an earnings per share of -$0.13. Analysts have an average one-year price target of $9.25 for TLSI, suggesting a significant upside, while GuruFocus estimates a GF Value of $5.1, indicating a 56.92% upside from the current price of $3.25. The company's average brokerage recommendation is "Outperform."

Nov 9, 2026

Delcath Systems reported record third-quarter 2026 revenue of $35.1 million, a 71% increase year-over-year, driven by HEPZATO KIT adoption and network expansion to 33 active U.S. treatment centers. The company achieved a gross margin of 89% and net income of $7 million, along with positive operating cash flow. Delcath raised its full-year 2026 revenue guidance to $115-117 million and is advancing its Phase 2 colorectal trial, expecting an interim analysis mid-2027, while expanding its pipeline with planned IND submissions for cholangiocarcinoma and an oxaliplatin-based PHP program.

Nov 9, 2026

Health Canada has approved the Dexcom G7 Continuous Glucose Monitoring System for use with myLoop, powered by CamAPS FX, making it Canada's only automated insulin delivery system approved for pregnant women with type 1 diabetes. This advancement provides a crucial new option for managing the complexities of diabetes during pregnancy, a period when insulin needs can vary significantly. The approval is supported by the AiDAPT trial, which demonstrated improved glucose control without increased hypoglycemia risk for women using CamAPS FX.

Nov 9, 2026

Piper Sandler has increased its price target for Stryker (NYSE:SYK) to $350.00 from $325.00, maintaining an "overweight" rating and suggesting a 7.6% upside. Despite the positive analyst sentiment, the medical technology company recently reported quarterly results slightly below estimates, with EPS of $3.52 versus $3.55 expected and revenue of $6.52 billion against $6.62 billion anticipated, though revenue still grew 7.6% year-over-year. The consensus among analysts remains a "Moderate Buy" with an average target price of $342.19.

Nov 9, 2026

Top Wall Street analysts have updated their ratings and price targets for several key companies. Notable changes include BTIG raising Magnite Inc's price target, Piper Sandler lowering Unusual Machines Inc's target, and Stifel downgrading DraftKings Inc to Hold. Additionally, Rothschild & Co upgraded Airbnb Inc, while Cantor Fitzgerald raised Block, Inc.'s price target.

Nov 9, 2026

JPMorgan Chase & Co. raised its price target for TransMedics Group (NASDAQ:TMDX) stock from $73.00 to $85.00, while maintaining a "neutral" rating. Despite the upgrade, the new target implies a potential downside of 3.67% from the company's previous close. The company recently surpassed quarterly earnings expectations, reporting EPS of $0.51 and revenue of $203.01 million, significantly exceeding analyst estimates.

Nov 9, 2026

The US Food and Drug Administration has declined to approve Novocure's Optune Mya device, designed for lung cancer patients with brain metastases, citing uncertainty about its clinical benefit. While no safety concerns were raised, preliminary results from a 2024 trial showed the device delayed brain tumor growth but did not achieve statistical significance for overall survival. Novocure plans to engage with the FDA to explore options for approval without requiring additional clinical studies.

Nov 9, 2026

Orthofix Medical ($OFIX) reported its Q3 2026 earnings, beating EPS estimates by $0.45 with $0.18 per share, but missed revenue estimates by $6.9 million, reporting $207.8 million. The article also details recent insider trading activity, institutional investor holdings, and analyst ratings, with a median price target of $17.0 for the stock.

Nov 9, 2026

This article lists 12 healthcare stocks that experienced significant movement in Monday's pre-market session. Six stocks saw gains, with MaxCyte (NASDAQ: MXCT) and Vir Biotechnology (NASDAQ: VIR) leading the increases, while another six stocks, including Zura Bio (NASDAQ: ZURA) and Faeth Therapeutics (NASDAQ: FTH), experienced declines. The article provides the percentage change, current stock price, and market capitalization for each company mentioned.

Nov 9, 2026

Profound Medical Corp reported a net loss of approximately $7.7 million, or $0.21 per common share, for the third quarter ended September 30, 2026. Despite the loss, the company saw an 86% year-over-year revenue increase to $9.8 million and expanded its gross margin to 78%. Profound Medical projects full-year 2026 revenue to be at least $25.0 million with a gross margin of 70% or higher.

Nov 9, 2026

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System, an innovative solution for Early Onset Scoliosis (EOS). This system aims to correct spinal deformities while preserving the potential for continued spinal growth in children. The successful limited launch highlighted strong demand and adoption, further solidifying OrthoPediatrics' commitment to pediatric-specific orthopedic solutions.

Nov 9, 2026

Hohimer Wealth Management LLC has acquired a new stake in Stryker Corporation, purchasing 16,826 shares valued at approximately $4.63 million in the third quarter. Other institutional investors like State Street Corp and Wellington Management Group LLP also adjusted their holdings. Despite the new investment, Stryker recently missed Q3 earnings estimates, reporting an EPS of $3.52 against a $3.55 consensus and revenue of $6.52 billion against $6.62 billion expected, though revenue still grew 7.6% year-over-year.

Nov 9, 2026

CenterBook Partners LP recently acquired a new stake of 131,685 shares in InMode Ltd., valued at approximately $1.87 million, representing 0.23% of the company. Other institutional investors also adjusted their holdings, with institutions and hedge funds collectively owning 68.04% of InMode. Despite InMode shares opening at $13.33, analysts maintain a consensus "Hold" rating with an average price target of $16.00.

Nov 9, 2026

USARAD Holdings, Inc., a wholly-owned subsidiary of Nanox Imaging Ltd., has announced an expanded collaboration with AZmed to further integrate AZmed's FDA-cleared X-ray AI solutions into USARAD's radiology workflows. This expansion builds on USARAD's existing use of AZmed's AI, including AZtrauma for musculoskeletal trauma and AZchest for chest X-rays, to enhance efficiency in prioritizing and reading studies. The integration will occur through Nanox Marketplace, facilitating automated study routing and DICOM transmission, allowing radiologists to access AI results within their existing OnePacs platform.

Nov 9, 2026

Carnegie Lake Advisors LLC significantly reduced its stake in Stryker Corporation by 97% in the third quarter of 2026. This comes as Stryker missed analysts' earnings and revenue estimates for the quarter, despite a year-over-year revenue increase. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $343.73.

Nov 9, 2026

Truist Securities analyst Richard Newitter raised the price target for Insulet Corporation (PODD) to $160. The article, updated on November 9, 2026, reports on this analyst rating change. The full details are available only to premium subscribers.

Nov 8, 2026

Myomo Inc (MYO) is scheduled to release its Q3 earnings report on November 9, 2026, after market close. The market is closely watching the company's Price-to-Sales ratio of 1.19, which is significantly below its historical median, suggesting subdued future growth expectations. Despite ongoing losses and weak financial strength, positive momentum and net insider buying, along with some guru accumulation, indicate cautious institutional interest.

Nov 8, 2026

RadNet, Inc. announced record quarterly revenue of $638.3 million and Adjusted EBITDA of $105.0 million for the third quarter of 2026, marking increases of 22.1% and 23.8% respectively, compared to the previous year. The company also revised its full-year 2026 financial guidance upwards for Imaging Center Revenue, Adjusted EBITDA, and Free Cash Flow, citing strong performance across its core imaging center business and growth in its Digital Health segment. Dr. Howard Berger, President and CEO, highlighted significant growth in advanced imaging volumes and the strategic opportunities presented by the pending acquisition of ONRAD.

Nov 8, 2026

Amgen has consistently raised its quarterly dividend since 2011, achieving a ninefold increase and compounding at about 16% annually. Despite this strong growth and solid coverage by free cash flow, the pace of dividend raises has slowed, with the latest increase being around 6%. The company faces challenges from patent cliffs and drug price controls, which could impact future dividend growth, even as debt declines and new drugs show strong performance.

Nov 8, 2026

Liontrust Investment Partners LLP has reduced its stake in MaxCyte Inc (MXCT) by selling 112,919 shares. Although the stock trades at a significant discount to its GF Value, GuruFocus flags it as a "Possible Value Trap" due to weak profitability and negative growth trends. The transaction reflects the firm's cautious approach to a loss-making life sciences company despite the apparent discount.

Nov 7, 2026

Waycross Partners LLC has made a new $27.85 million investment in Stryker Corporation, acquiring 101,131 shares in the third quarter, making it their 22nd largest holding. The stock currently has a "Moderate Buy" average rating from analysts, though several have recently lowered their price targets. Stryker's latest quarterly results missed earnings and revenue estimates, causing its shares to trade down.

Nov 7, 2026

Rakuten Investment Management Inc. initiated a position in STERIS plc during the third quarter, purchasing 17,498 shares valued at approximately $3.69 million. STERIS reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.69 per share. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $276.33.

Nov 7, 2026

American Express (AXP) CEO Stephen Squeri sold $99 million of exercised stock options on November 4, 2026, one day before a significant tech-led market selloff that saw the Nasdaq Composite lose $2.5 trillion. While the timing appears problematic, AXP shares traded higher on November 5 than Squeri's average sale price, mitigating the appearance of a perfectly timed exit. This sale is also part of a pattern for Squeri, who made similar large-scale sales in 2022 and 2024.

Nov 7, 2026

Wall Street Zen has upgraded PROCEPT BioRobotics (NASDAQ:PRCT) from a "sell" to a "hold" rating, aligning with the overall analyst consensus and a target price of $25.25. This upgrade comes despite the company missing analyst expectations in its latest quarterly report, showing a loss of $0.46 per share and revenue of $98.29 million, although revenue did grow 18% year-over-year. Shares opened at $20.62, within a 52-week range of $16.67 to $38.11, and institutional investors have recently adjusted their holdings in the medical technology company.

Nov 7, 2026

This article highlights three medical device companies—Abbott Laboratories, Stryker, and Becton Dickinson—known for consistently increasing their dividends due to the stable demand for their products. Becton Dickinson stands out with 55 consecutive years of dividend raises, while Abbott boasts 54 years and a commitment to further increases. Stryker, despite a lower yield, has the most room for future dividend growth given its low payout ratio.

Nov 7, 2026

DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, without company-specific news, echoing similar declines in peers Insulet and Tandem Diabetes Care. Tandem's earnings call revealed slower-than-expected pharmacy distribution which could impact 2027 revenue growth, potentially affecting DexCom due to its presence in the same diabetes market. Despite this recent fall, DexCom's shares have returned 34.0% over the past year, significantly outperforming the S&P 500.

Nov 7, 2026

Jake Leach, CEO of Dexcom, rose from a $10-an-hour lab dishwasher to leading a $30 billion healthcare company without ever asking for a promotion. His career path was shaped by hard work, a childhood fascination with engineering, and a personal connection to diabetes through his grandfather. Leach advises young professionals to take initiative, solve big problems, and volunteer for tasks outside their immediate responsibilities to become more valuable leaders.

Nov 7, 2026

Wall Street Zen upgraded TransMedics Group (NASDAQ:TMDX) from a "sell" to a "hold" rating. The company reported strong third-quarter results, beating analyst estimates with $203.0 million in revenue and $0.51 EPS, and raised its 2026 revenue outlook. Despite these positive financial indicators, some key catalysts have been delayed to early 2027.

Nov 7, 2026

Wall Street Zen has upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, despite mixed views from other analysts, which result in a consensus "hold" rating with an average price target of $5.25. The stock opened at $2.02, with a 52-week range of $1.42–$3.47 and a market capitalization of approximately $407 million. Institutional investors and hedge funds hold 78.37% of Cerus shares, while an insider recently sold 30,000 shares.

Nov 7, 2026

Boston Trust Walden Corp reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 5.3% in the third quarter, selling 13,624 shares while retaining a substantial holding valued at over $21 million. This reduction occurred despite other institutional investors, like Assenagon Asset Management S.A., increasing their positions. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates with EPS of $0.80 and revenue of $1.72 billion, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $108.88.